There's Been a Big Improvement in Lung Cancer Survival

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 19, 2024.

By Carole Tanzer Miller HealthDay Reporter

TUESDAY, Nov. 19, 2024 -- More people with lung cancer are living longer, but it remains America's deadliest cancer, a new state-by-state report shows.

"There is more work to do, but I am incredibly optimistic about the future of lung cancer care," said Harold Wimmer, president and CEO of the American Lung Association (ALA), which documents improved survival rates and opportunities to do more in its 2024 "State of Lung Cancer" report.

In the past five years, the lung cancer survival rate has improved 26%, according to the report. It credits deployment of biomarker testing -- which looks for changes in a tumor's DNA -- as a key factor. Biomarker testing can help tailor treatments to individual patients, it points out.

But, the report notes, access to the testing, which is also called molecular, genomic or genetic testing, is uneven. Only 15 states require comprehensive insurance coverage for it, while five more require some insurance plans to include it.

"This year's 'State of Lung Cancer' report provides a path for states and the federal government to take to improve the lives of people living with this devastating disease," Wimmer said in an ALA news release. "Increasing lung cancer screening rates and expanding biomarker testing are enormous opportunities to catch cancer earlier and provide the best treatments for people diagnosed with the disease."

The new report tracks both nationwide and state-by-state screening rates. Last year, 16% of those eligible nationwide were screened for lung cancer, according to the report.

Rhode Island had the nation's best screening rate (28.6%), while Wyoming had the worst (8.6%). The report projects that nearly 235,000 people nationwide will receive a lung cancer diagnosis this year.

Because many patients aren't diagnosed until their lung cancer is in a late stage, when it is less likely to be curable, the five-year survival rate is 28.4%. That's the percentage of patients who were alive five years after their diagnosis.

Massachusetts had the top survival rate, 37.9%. Oklahoma's 22.2% survival rate was the worst.

Nationwide, 27.4% of lung cancers are diagnosed at an early stage, and those have a higher survival rate, at 64%, according to the report. But 43% of cases aren't caught until a late stage. At that point, the survival rate plummets to 9%.

Massachusetts had the best rate of early diagnosis, 34.7%, and Hawaii the worst, 21.1%.

When diagnosed early, before it has spread, lung cancer is often treated with surgery. Nationwide, 20.7% of cases were treated surgically.

Roughly the same percentage of cases -- 20.9% -- were not treated at all. The report said there are many reasons why, but lack of provider or patient knowledge, cancer-related stigma, fatalism after diagnosis or cost should never be a factor.

Nevada had the highest lack-of-treatment rate -- 36.7% -- and Massachusetts, the lowest, 13.2%.

As is the case across health care, the report noted that minorities have worse outcomes than white patients. They are less likely to be diagnosed early or undergo surgery and are more likely to go untreated.

"More must be done to eliminate lung cancer health disparities," the ALA said.

It called on all states to require insurance coverage of biomarker testing.

Sources

  • American Lung Association, news release, Nov. 19, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-11-20 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords